Optiver Holding
MLYS icon

Optiver Holding’s Mineralys Therapeutics MLYS Stock Holding History

Optiver Holding’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99K Buy
148
+68
+85% +$1.87K ﹤0.01% 2069
2026
Q1 		$2.17K Buy
80
+38
+90% +$1.11K ﹤0.01% 1812
2025
Q4 		$1.52K Sell
42
-244
-85% -$9.79K ﹤0.01% 2118
2025
Q3 		$10.8K Buy
+286
New +$6.19K ﹤0.01% 1248

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Optiver Holding's MLYS Position: Q2 2026 in Review

Optiver Holding increased its Mineralys Therapeutics (MLYS) stake by 85% in Q2 2026, buying an estimated $1.87K and bringing the position to 148 shares worth $3.99K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Optiver Holding first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.8K in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Optiver Holding held 148 shares of Mineralys Therapeutics worth $3.99K as of Q2 2026.
  • Optiver Holding bought 68 Mineralys Therapeutics shares in Q2 2026, an estimated $1.87K.
  • Mineralys Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2069 holding.
  • Optiver Holding first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Mineralys Therapeutics position peaked at $10.8K in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.